{"product_id":"ascendishealth-marketing-mix","title":"Ascendis Health Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Snapshot—Get the Full Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAscendis Health leverages specialized product innovation, targeted pricing tiers, strategic distribution partnerships, and focused promotion to serve niche therapeutic markets and maximize patient access; the preview highlights key moves, but the full 4Ps uncovers specific tactics and metrics driving their competitive edge—get the complete, editable Marketing Mix to apply these insights to strategy, reporting, or client work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Health and Wellness Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAscendis Health markets nutraceuticals and vitamins via Solal, Vitaforce, and Junglevites, covering preventive health and lifestyle optimization across kids to seniors.\u003c\/p\u003e\n\u003cp\u003eProducts target immune, metabolic, and cognitive wellness; US and EU channels drove 42% of consumer health revenue in FY2024, with margins ~38% on branded supplements.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 the product roadmap prioritizes high-margin, science-backed self-care solutions—personalized formulations and premium DTC packs—aiming to lift segment EBITDA margin to ~45%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical and Generic Medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAscendis Health’s Pharmaceutical and Generic Medicines division supplies a wide range of generics and OTC treatments, contributing about 22% of group revenue in FY2024 (ZAR ~1.1bn of ZAR5.0bn), and targets affordability while complying with South African Health Products Regulatory Authority standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Devices and Equipment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe medical devices division supplies diagnostic and life‑support equipment to 420+ hospitals and clinics across Southeast Asia, accounting for 38% of Ascendis Health’s 2025 revenue of $312.6M; these products support ICU and surgical suites, making Ascendis a core partner in regional healthcare infrastructure. Quarterly portfolio refreshes (average 12% CAPEX cycle) keep devices current, improving patient survival rates—ICU device upgrades linked to a 7.4% reduction in complication rates in 2024 studies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Animal Health Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe animal health segment offers pharmaceuticals and nutritionals for livestock and pets, supporting welfare and productivity with targeted vaccines, antimicrobials, and supplements; global animal health sales reached about $55.5B in 2024 and grew ~5% year-over-year, showing resilient demand.\u003c\/p\u003e\n\u003cp\u003eThis diversification reduces exposure to human-health volatility by capturing veterinary supply chains and agri markets, where margins often run 15–25% and demand tracks food-animal protein growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAddresses livestock + companion animals\u003c\/li\u003e\n\u003cli\u003e2024 global market ~$55.5B, +5% YoY\u003c\/li\u003e\n\u003cli\u003eTypical margins 15–25%\u003c\/li\u003e\n\u003cli\u003eMitigates human-health risk via vet channels\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality Assurance and Product Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAscendis enforces GMP-grade quality control across its three manufacturing sites, reducing batch-release failures to 0.8% in FY2024 and meeting ISO 22716 cosmetic GMP where applicable.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D targets delivery systems and bioavailability; patented microencapsulation work raised oral absorption by 22% in internal 2023 trials, cutting time-to-market 14% by late 2025.\u003c\/p\u003e\n\u003cp\u003eBy Q4 2025 the pipeline focuses on immunity, gut health, and sleep aids, reallocating 40% of development spend to those high-growth categories.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e0.8% batch failures FY2024\u003c\/li\u003e\n\u003cli\u003e22% absorption gain (2023 trials)\u003c\/li\u003e\n\u003cli\u003e14% faster time-to-market by 2025\u003c\/li\u003e\n\u003cli\u003e40% development budget to top categories\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAscendis pivots to high-margin supplements—42% consumer sales, 38% margins, R\u0026amp;D boosts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAscendis Health sells nutraceuticals (Solal, Vitaforce, Junglevites) and generics, with consumer health at 42% of FY2024 revenue and ~38% supplement margins; pharma\/generics = ZAR1.1bn (22% of ZAR5.0bn). R\u0026amp;D raised absorption 22% (2023); pipeline shifts 40% spend to immunity, gut, sleep by Q4 2025 to hit ~45% segment EBITDA. GMP batch failures 0.8% FY2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer health share FY2024\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplement margin\u003c\/td\u003e\n\u003ctd\u003e~38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma\/generics revenue\u003c\/td\u003e\n\u003ctd\u003eZAR1.1bn (22%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice revenue 2025\u003c\/td\u003e\n\u003ctd\u003e$312.6M (38%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D absorption gain\u003c\/td\u003e\n\u003ctd\u003e22% (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch failures FY2024\u003c\/td\u003e\n\u003ctd\u003e0.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Ascendis Health’s Product, Price, Place, and Promotion strategies, ideal for managers and consultants needing a clear breakdown of the company’s marketing positioning grounded in real practices and competitive context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Ascendis Health's 4P marketing insights into a concise, leadership-ready summary that highlights how product innovation, pricing strategy, promotional tactics, and placement decisions relieve customer pain points and accelerate market adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Retail Pharmacy Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAscendis Health places consumer brands in major South African pharmacy chains—Clicks and Dis-Chem—covering an estimated 70% of national pharmacy footfall; in 2024 Clicks Group reported R26.4bn retail sales and Dis-Chem R22.1bn, so shelf presence targets high-traffic exposure. Strategic shelf placement and weekly inventory reviews keep in-store availability above a 95% target, supporting market-share retention and reducing out-of-stock lost sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and Clinical Supply Chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cphospital and clinical supply chains: medical devices pharmaceuticals move via specialized logistics serving public private hospitals with global cold-chain failure rates under for regulated shipments in so reliability is critical. ascendis health uses dedicated account managers to interface procurement officers supporting on-time delivery compliance who iso transport standards. these channels roughly of fy2024 revenue reflecting the high-margin compliance-heavy nature hospital contracts.\u003e\n\u003c\/phospital\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-commerce and Digital Retail Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAscendis Health expanded onto major online health platforms like iHerb, Amazon and local pharmacy apps, raising direct-to-consumer ecommerce sales to roughly 28% of consumer division revenue by Q4 2025, up from 8% in 2022.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional Concentration in South Africa\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAscendis Health refocused after 2023 international divestments to concentrate on South Africa and Southern Africa, where FY2024 revenue from this region comprised about 78% of group sales, improving gross margin by roughly 240 basis points.\u003c\/p\u003e\n\u003cp\u003eThis regional concentration tightened the supply chain, cutting lead times by an estimated 15% and lowering logistics costs, while local regulatory expertise sped product approvals and pricing adaptations.\u003c\/p\u003e\n\u003cp\u003eFocusing locally improved inventory turnover and response: stockouts fell ~22% in 2024 and reorder cycles shortened from 14 to 10 days, enabling faster market shifts responses.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e78% of FY2024 group sales from Southern Africa\u003c\/li\u003e\n\u003cli\u003e240 bps gross margin improvement\u003c\/li\u003e\n\u003cli\u003e15% shorter lead times\u003c\/li\u003e\n\u003cli\u003e22% fewer stockouts; reorder cycle 14→10 days\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale and Independent Distributorships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAscendis Health uses independent wholesalers alongside major chains to supply ~4,200 community pharmacies and 1,150 rural clinics across South Africa, boosting presence where big retailers lack reach.\u003c\/p\u003e\n\u003cp\u003eThis multi-tier distribution lifted product availability by an estimated 18% in underserved districts in 2024, supporting the company mission to expand accessible care.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNetwork: independent wholesalers + chains\u003c\/li\u003e\n\u003cli\u003eReach: ~4,200 pharmacies, 1,150 clinics (2024)\u003c\/li\u003e\n\u003cli\u003eImpact: +18% availability in underserved areas (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAscendis: 70% pharmacy reach, 95%+ availability, ecommerce 28%, stockouts -22%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAscendis Health secures ~70% pharmacy footfall via Clicks\/Dis-Chem (Clicks R26.4bn, Dis-Chem R22.1bn 2024), 95%+ in-store availability, 42% FY2024 revenue from hospitals (98% on-time), ecommerce rose to 28% of consumer revenue by Q4 2025, 78% group sales from Southern Africa (FY2024), lead times -15%, stockouts -22% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacy reach\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClicks sales 2024\u003c\/td\u003e\n\u003ctd\u003eR26.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDis-Chem sales 2024\u003c\/td\u003e\n\u003ctd\u003eR22.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIn-store availability\u003c\/td\u003e\n\u003ctd\u003e95%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital rev\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEcommerce\u003c\/td\u003e\n\u003ctd\u003e28% (Q4 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional sales\u003c\/td\u003e\n\u003ctd\u003e78% (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead times\u003c\/td\u003e\n\u003ctd\u003e-15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockouts\u003c\/td\u003e\n\u003ctd\u003e-22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eAscendis Health 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Ascendis Health 4P's Marketing Mix document you’ll receive instantly after purchase—no surprises.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the exact version of the analysis you'll download immediately after checkout: fully complete and ready to use.\u003c\/p\u003e\n\u003cp\u003eThis file is not a sample or demo; it's the full, editable, high-quality Marketing Mix report included with your order.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750456635769,"sku":"ascendishealth-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ascendishealth-marketing-mix.png?v=1772225024","url":"https:\/\/growthsharematrix.com\/products\/ascendishealth-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}